AstraZeneca Results Presentation Deck
Total Revenue
9M 2023 - Reported profit and loss
- Product Sales
- Alliance Revenue
- Collaboration Revenue
CEO Opening Remarks
Product Sales Gross margin
Total operating expense¹
- R&D expense
- SG&A expense
Other operating income and
expense
Operating profit
Tax rate
Reported EPS
9M 2023
$m
33,787
32,466
1,004
317
81.6%
(22,101)
(7,862)
(13,845)
1,233
Financial Results
6,959
17%
$3.22
CER change
%
5
4
99
(28)
+12 pp
6
12
2
>3x
>2x
>2x
Oncology
% Total
Revenue
100
96
3
1
65
23
41
4
21
BioPharmaceuticals
Q3 2023
$m
11,492
11,018
377
97
81.0%
(7,513)
(2,584)
(4,800)
70
1,954
17%
$0.89
Rare Disease
CER change
%
6
5
75
(47)
+10 pp
12
(33)
69
(6)
Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
9 Absolute values at actual exchange rates; changes at CER. Product Sales Gross margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
1. Total operating expense includes distribution, R&D and SG&A expenses. R&D = Research & Development; SG&A = Sales, General & Administrative; EPS = earnings per share; pp = percentage points; CER = constant exchange rates.
CEO Closing Remarks
% Total
Revenue
100
96
3
1
65
22
42
1
17
AView entire presentation